Selected research
Industry Research
Virus like Particle (VLP) Vaccines Industry Research Report 2026
Market perspective
The global Virus like Particle (VLP) Vaccines market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Virus like Particle (VLP) Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Virus like Particle (VLP) Vaccines is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Virus like Particle (VLP) Vaccines is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Virus like Particle (VLP) Vaccines include WuXi Biologics, Junshi Biosciences, Luye Pharma Group, Chengdu Kanghua Biological Products Co., Ltd., Shanghai Bovax Biotechnology Co., Ltd., VBI Vaccines Inc, Premas Biotech, Creative Diagnostics and Creative Biostructure, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Virus like Particle (VLP) Vaccines market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Virus like Particle (VLP) Vaccines Market by Company
WuXi Biologics
Junshi Biosciences
Luye Pharma Group
Chengdu Kanghua Biological Products Co., Ltd.
Shanghai Bovax Biotechnology Co., Ltd.
VBI Vaccines Inc
Premas Biotech
Creative Diagnostics
Creative Biostructure
Coriolis
Charles River Laboratories
BioAgilytix
AstraZeneca Group (Icosavax)
Virus like Particle (VLP) Vaccines Segment by Type
Prophylactic Vaccine
Therapeutic Vaccine
Virus like Particle (VLP) Vaccines Segment by Application
Human Papillomavirus (HPV)
Hepatitis E Virus (HEV)
Hepatitis B Virus (HBV)
Other
Virus like Particle (VLP) Vaccines Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Virus like Particle (VLP) Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Virus like Particle (VLP) Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Virus like Particle (VLP) Vaccines.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Virus like Particle (VLP) Vaccines manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Virus like Particle (VLP) Vaccines by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Virus like Particle (VLP) Vaccines in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Prophylactic Vaccine
- Therapeutic Vaccine
Applications
- Human Papillomavirus (HPV)
- Hepatitis E Virus (HEV)
- Hepatitis B Virus (HBV)
- Other
Companies covered
- WuXi Biologics
- Junshi Biosciences
- Luye Pharma Group
- Chengdu Kanghua Biological Products Co., Ltd.
- Shanghai Bovax Biotechnology Co., Ltd.
- VBI Vaccines Inc
- Premas Biotech
- Creative Diagnostics
- Creative Biostructure
- Coriolis
- Charles River Laboratories
- BioAgilytix
- AstraZeneca Group (Icosavax)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Virus like Particle (VLP) Vaccines Market Size (2021-2032)
- 2.2.2 Global Virus like Particle (VLP) Vaccines Sales (2021-2032)
- 2.2.3 Global Virus like Particle (VLP) Vaccines Market Average Price (2021-2032)
- 2.3 Virus like Particle (VLP) Vaccines by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Prophylactic Vaccine
- 2.3.3 Therapeutic Vaccine
- 2.4 Virus like Particle (VLP) Vaccines by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Human Papillomavirus (HPV)
- 2.4.3 Hepatitis E Virus (HEV)
- 2.4.4 Hepatitis B Virus (HBV)
- 2.4.5 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Virus like Particle (VLP) Vaccines Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Virus like Particle (VLP) Vaccines Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Virus like Particle (VLP) Vaccines Revenue of Manufacturers (2021-2026)
- 3.4 Global Virus like Particle (VLP) Vaccines Average Price by Manufacturers (2021-2026)
- 3.5 Global Virus like Particle (VLP) Vaccines Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Virus like Particle (VLP) Vaccines, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Virus like Particle (VLP) Vaccines, Product Type & Application
- 3.8 Global Manufacturers of Virus like Particle (VLP) Vaccines, Established Date
- 3.9 Global Virus like Particle (VLP) Vaccines Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 WuXi Biologics
- 4.1.1 WuXi Biologics Company Information
- 4.1.2 WuXi Biologics Business Overview
- 4.1.3 WuXi Biologics Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 WuXi Biologics Virus like Particle (VLP) Vaccines Product Portfolio
- 4.1.5 WuXi Biologics Recent Developments
- 4.2 Junshi Biosciences
- 4.2.1 Junshi Biosciences Company Information
- 4.2.2 Junshi Biosciences Business Overview
- 4.2.3 Junshi Biosciences Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Junshi Biosciences Virus like Particle (VLP) Vaccines Product Portfolio
- 4.2.5 Junshi Biosciences Recent Developments
- 4.3 Luye Pharma Group
- 4.3.1 Luye Pharma Group Company Information
- 4.3.2 Luye Pharma Group Business Overview
- 4.3.3 Luye Pharma Group Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Luye Pharma Group Virus like Particle (VLP) Vaccines Product Portfolio
- 4.3.5 Luye Pharma Group Recent Developments
- 4.4 Chengdu Kanghua Biological Products Co., Ltd.
- 4.4.1 Chengdu Kanghua Biological Products Co., Ltd. Company Information
- 4.4.2 Chengdu Kanghua Biological Products Co., Ltd. Business Overview
- 4.4.3 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Chengdu Kanghua Biological Products Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio
- 4.4.5 Chengdu Kanghua Biological Products Co., Ltd. Recent Developments
- 4.5 Shanghai Bovax Biotechnology Co., Ltd.
- 4.5.1 Shanghai Bovax Biotechnology Co., Ltd. Company Information
- 4.5.2 Shanghai Bovax Biotechnology Co., Ltd. Business Overview
- 4.5.3 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Shanghai Bovax Biotechnology Co., Ltd. Virus like Particle (VLP) Vaccines Product Portfolio
- 4.5.5 Shanghai Bovax Biotechnology Co., Ltd. Recent Developments
- 4.6 VBI Vaccines Inc
- 4.6.1 VBI Vaccines Inc Company Information
- 4.6.2 VBI Vaccines Inc Business Overview
- 4.6.3 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 VBI Vaccines Inc Virus like Particle (VLP) Vaccines Product Portfolio
- 4.6.5 VBI Vaccines Inc Recent Developments
- 4.7 Premas Biotech
- 4.7.1 Premas Biotech Company Information
- 4.7.2 Premas Biotech Business Overview
- 4.7.3 Premas Biotech Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Premas Biotech Virus like Particle (VLP) Vaccines Product Portfolio
- 4.7.5 Premas Biotech Recent Developments
- 4.8 Creative Diagnostics
- 4.8.1 Creative Diagnostics Company Information
- 4.8.2 Creative Diagnostics Business Overview
- 4.8.3 Creative Diagnostics Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Creative Diagnostics Virus like Particle (VLP) Vaccines Product Portfolio
- 4.8.5 Creative Diagnostics Recent Developments
- 4.9 Creative Biostructure
- 4.9.1 Creative Biostructure Company Information
- 4.9.2 Creative Biostructure Business Overview
- 4.9.3 Creative Biostructure Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Creative Biostructure Virus like Particle (VLP) Vaccines Product Portfolio
- 4.9.5 Creative Biostructure Recent Developments
- 4.10 Coriolis
- 4.10.1 Coriolis Company Information
- 4.10.2 Coriolis Business Overview
- 4.10.3 Coriolis Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Coriolis Virus like Particle (VLP) Vaccines Product Portfolio
- 4.10.5 Coriolis Recent Developments
- 4.11 Charles River Laboratories
- 4.11.1 Charles River Laboratories Company Information
- 4.11.2 Charles River Laboratories Business Overview
- 4.11.3 Charles River Laboratories Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Charles River Laboratories Virus like Particle (VLP) Vaccines Product Portfolio
- 4.11.5 Charles River Laboratories Recent Developments
- 4.12 BioAgilytix
- 4.12.1 BioAgilytix Company Information
- 4.12.2 BioAgilytix Business Overview
- 4.12.3 BioAgilytix Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 BioAgilytix Virus like Particle (VLP) Vaccines Product Portfolio
- 4.12.5 BioAgilytix Recent Developments
- 4.13 AstraZeneca Group (Icosavax)
- 4.13.1 AstraZeneca Group (Icosavax) Company Information
- 4.13.2 AstraZeneca Group (Icosavax) Business Overview
- 4.13.3 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 AstraZeneca Group (Icosavax) Virus like Particle (VLP) Vaccines Product Portfolio
- 4.13.5 AstraZeneca Group (Icosavax) Recent Developments
5 Global Virus like Particle (VLP) Vaccines Market Scenario by Region
- 5.1 Global Virus like Particle (VLP) Vaccines Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Virus like Particle (VLP) Vaccines Sales by Region: 2021-2032
- 5.2.1 Global Virus like Particle (VLP) Vaccines Sales by Region: 2021-2026
- 5.2.2 Global Virus like Particle (VLP) Vaccines Sales by Region: 2027-2032
- 5.3 Global Virus like Particle (VLP) Vaccines Revenue by Region: 2021-2032
- 5.3.1 Global Virus like Particle (VLP) Vaccines Revenue by Region: 2021-2026
- 5.3.2 Global Virus like Particle (VLP) Vaccines Revenue by Region: 2027-2032
- 5.4 North America Virus like Particle (VLP) Vaccines Market Facts & Figures by Country
- 5.4.1 North America Virus like Particle (VLP) Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Virus like Particle (VLP) Vaccines Sales by Country (2021-2032)
- 5.4.3 North America Virus like Particle (VLP) Vaccines Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Virus like Particle (VLP) Vaccines Market Facts & Figures by Country
- 5.5.1 Europe Virus like Particle (VLP) Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Virus like Particle (VLP) Vaccines Sales by Country (2021-2032)
- 5.5.3 Europe Virus like Particle (VLP) Vaccines Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Virus like Particle (VLP) Vaccines Market Facts & Figures by Country
- 5.6.1 Asia Pacific Virus like Particle (VLP) Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Virus like Particle (VLP) Vaccines Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Virus like Particle (VLP) Vaccines Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Virus like Particle (VLP) Vaccines Market Facts & Figures by Country
- 5.7.1 South America Virus like Particle (VLP) Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Virus like Particle (VLP) Vaccines Sales by Country (2021-2032)
- 5.7.3 South America Virus like Particle (VLP) Vaccines Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Virus like Particle (VLP) Vaccines Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Virus like Particle (VLP) Vaccines Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Virus like Particle (VLP) Vaccines Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Virus like Particle (VLP) Vaccines Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Virus like Particle (VLP) Vaccines Sales by Type (2021-2032)
- 6.1.1 Global Virus like Particle (VLP) Vaccines Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Virus like Particle (VLP) Vaccines Sales Market Share by Type (2021-2032)
- 6.2 Global Virus like Particle (VLP) Vaccines Revenue by Type (2021-2032)
- 6.2.1 Global Virus like Particle (VLP) Vaccines Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Virus like Particle (VLP) Vaccines Revenue Market Share by Type (2021-2032)
- 6.3 Global Virus like Particle (VLP) Vaccines Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Virus like Particle (VLP) Vaccines Sales by Application (2021-2032)
- 7.1.1 Global Virus like Particle (VLP) Vaccines Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Virus like Particle (VLP) Vaccines Sales Market Share by Application (2021-2032)
- 7.2 Global Virus like Particle (VLP) Vaccines Revenue by Application (2021-2032)
- 7.2.1 Global Virus like Particle (VLP) Vaccines Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Virus like Particle (VLP) Vaccines Revenue Market Share by Application (2021-2032)
- 7.3 Global Virus like Particle (VLP) Vaccines Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Virus like Particle (VLP) Vaccines Value Chain Analysis
- 8.1.1 Virus like Particle (VLP) Vaccines Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Virus like Particle (VLP) Vaccines Production Mode & Process
- 8.2 Virus like Particle (VLP) Vaccines Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Virus like Particle (VLP) Vaccines Distributors
- 8.2.3 Virus like Particle (VLP) Vaccines Customers
9 Global Virus like Particle (VLP) Vaccines Analyzing Market Dynamics
- 9.1 Virus like Particle (VLP) Vaccines Industry Trends
- 9.2 Virus like Particle (VLP) Vaccines Industry Drivers
- 9.3 Virus like Particle (VLP) Vaccines Industry Opportunities and Challenges
- 9.4 Virus like Particle (VLP) Vaccines Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst